Seaside Therapeutics
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Seaside Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Seaside Therapeutics: 12 sponsored US clinical trials, none currently recruiting.
Seaside Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 8 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Fragile X Syndrome, with 1 trials.
Top-decile sponsor footprint
Seaside Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (66.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
An Open Label Extension Study in Subjects With Fragile X Syndrome
NCT01555333
Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01706523
Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome
NCT01325220
Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome
NCT01282268
Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
NCT01288716
An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders
NCT01064973
An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome
NCT01013480
A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107
NCT00965432
Biomarker and DNA Collection in Subjects Participating in Protocol 22003
NCT00892580
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
NCT00846547
Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001
NCT00823368
Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome
NCT00788073
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 4 |
Therapeutic Areas
How the Seaside Therapeutics archive is shaped
12 indexed studies, none listed as recruiting (0% open); 8 completed (67%).
Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Fragile X Syndrome (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Seaside Therapeutics: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Seaside Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Seaside Therapeutics page
12 registered trials is a research-attention snapshot, not an endorsement of Seaside Therapeutics or any single study.
- None of Seaside Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Fragile X Syndrome is the condition Seaside Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Fragile X Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Seaside Therapeutics pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.